Trinity Biotech (TRIB) AI Stock Analysis

• Market Cap: $13.94M
• Dividend Yield: N/A
• Average Volume (3M): 1.61M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.47
• Revenue Growth: 8.31%
• EPS Growth: 9.98%
• Country: US
• Employees: 380
• Sector: Healthcare
• Sector Strength: 39
• Industry: Medical - Diagnostics & Research
• EPS (TTM): N/A
• Shares Outstanding: 18,632,019
• 10 Day Avg. Volume: 4,746,522
• 30 Day Avg. Volume: 1,610,422
• PEG Ratio: 0.01
• Price to Book (P/B): -0.26
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.75
• Enterprise Value/Market Cap: 7.73
• Enterprise Value/Revenue: 0.46
• Enterprise Value/Gross Profit: 5.15
• Enterprise Value/Ebitda: -1.69
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 49 Neutral
• Price Target: $0.50 ▼(-33.33%Downside)

Trinity Biotech's overall score is primarily impacted by its weak financial performance, characterized by declining revenues, high debt levels, and negative equity. While there are some positive signals in technical analysis, the lack of positive valuation metrics further weighs down the score. Strategic changes are needed to improve financial stability and growth.

Trinity Biotech Business Overview & Revenue Model

Company Description

Trinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Africa, Asia, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease; sexually transmitted diseases consisting syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes. It also develops, manufactures, and sells products in the immunofluorescence assay, enzyme-linked immunosorbent, western blot, and line immunoassay formats; and provides reagent products, such as ACE, bile acids, lactate, oxalate, and glucose-6-phosphate dehydrogenase for diagnosis of liver and kidney diseases, as well as haemolytic anaemia. In addition, the company sells raw materials to the life sciences industry and research institutes. It serves public health authorities, non-governmental organisations, and clinical and reference laboratories through its direct sales force, as well as through a network of independent distributors and strategic partners. Trinity Biotech plc was incorporated in 1992 and is headquartered in Bray, Ireland.

How the Company Makes Money

Trinity Biotech makes money primarily through the sale of its diagnostic products across multiple healthcare sectors. Its revenue model is built on the direct sale of diagnostic tests and the provision of related services to healthcare providers, including hospitals and laboratories. Key revenue streams include product sales from its infectious disease diagnostics, clinical chemistry tests, and point-of-care tests. Additionally, Trinity Biotech benefits from strategic partnerships and collaborations with other healthcare organizations, enhancing its product distribution and market reach. The company also generates revenue through the supply of raw materials and components for diagnostic test manufacturing.

Trinity Biotech Financial Statement Overview

Summary

Trinity Biotech is experiencing significant financial challenges, with declining revenues, high debt levels, and negative equity. The company faces risks related to financial stability and sustainability. While there are some improvements in operating cash flows, overall financial health is weak, requiring strategic interventions to restore growth and stability.

Income Statement

Trinity Biotech has been experiencing declining revenues and profitability in recent years. The gross profit margin has decreased, and the company has been running at a net loss, with net profit margins consistently negative. The revenue growth rate is negative, indicating shrinking sales year-over-year. Both EBIT and EBITDA margins have also been negative, reflecting operational inefficiencies and challenges in covering operational costs.

Balance Sheet

The balance sheet shows significant financial distress, with negative stockholders' equity indicating more liabilities than assets. The debt-to-equity ratio is not calculable due to negative equity, but high total debt levels are concerning. The equity ratio is negative, highlighting an unsustainable financial structure. Return on equity is negative as well, reflecting ongoing losses.

Cash Flow

Cash flow metrics indicate challenges but also some operational cash inflow improvements in the latest year. Free cash flow remains negative, though the operating cash flow to net income ratio suggests some improvement in cash generation relative to net losses. However, consistent negative free cash flow indicates cash management issues.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	61.55M	56.83M	74.78M	92.97M	101.98M
Gross Profit	21.44M	19.45M	22.05M	38.08M	48.58M
EBITDA	-16.91M	-24.10M	-16.71M	10.59M	21.52M
Net Income	-31.79M	-24.02M	-41.00M	875.00K	-6.01M
Balance Sheet
Total Assets	103.29M	59.44M	92.10M	118.89M	130.40M
Cash, Cash Equivalents and Short-Term Investments	5.17M	3.69M	6.58M	25.91M	27.33M
Total Debt	100.76M	67.43M	58.26M	99.16M	104.34M
Total Liabilities	138.47M	83.38M	94.28M	119.21M	132.62M
Stockholders Equity	-35.18M	-23.95M	-2.18M	-319.00K	-2.22M
Cash Flow
Free Cash Flow	-14.26M	-14.26M	-6.90M	4.55M	13.56M
Operating Cash Flow	-4.19M	-11.56M	-921.00K	13.24M	23.75M
Investing Cash Flow	-22.97M	24.76M	-5.98M	-8.69M	-10.20M
Financing Cash Flow	28.81M	-16.04M	-12.32M	-6.02M	-2.72M

Trinity Biotech Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.75
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TRIB, the sentiment is Positive. The current price of 0.75 is above the 20-day moving average (MA) of 0.65, above the 50-day MA of 0.70, and below the 200-day MA of 0.95, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 58.60 is Neutral, neither overbought nor oversold. The STOCH value of 52.22 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TRIB.

Trinity Biotech Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PRPO	65 Neutral	$18.22M	―	-25.29%	―	26.67%	44.02%
INBS	62 Neutral	$12.30M	―	-126.34%	―	3.87%	91.76%
TRIB	49 Neutral	$13.94M	―	77.20%	―	8.31%	9.98%
Sector *	49 Neutral	AU$2.49B	4.37	-64.25%	2.83%	36.51%	13.14%
BIAF	42 Neutral	$7.75M	―	-290.85%	―	78.40%	22.41%
BNGO	41 Neutral	$11.34M	―	-127.82%	―	-24.04%	84.11%
MYNZ	41 Neutral	$5.46M	―	-809.29%	―	―	―